AstraZeneca v European Commission: Case C-457/10 P

Introduction -

On 6 December 2012, the European Court of Justice (the “ECJ”) upheld the judgment of the General Court (“GC”), which found that AstraZeneca (“AZ”) abused its dominant position on the market for proton pump inhibitors (“PPIs”) by misleading patent authorities and misusing the regulatory system in order to prevent generic competition against its anti-ulcer medicine, Losec (omeprazole), in certain markets. The ECJ also rejected two cross-appeals brought by the European Commission (“Commission”) and the European Federation of Pharmaceutical Industries and Associations (“EFPIA”).

Despite not changing the outcome of the case (or the EUR 52.5 million fine on AZ), the judgment contains some interesting statements of law which may have wider relevance beyond the pharmaceutical sector. The ECJ’s comments appear to limit the scope of the case in terms of precedent value for the pharma sector, confining it to relatively narrow facts. This may have a positive impact in removing uncertainty and thus helping to ensure continued innovation and dynamic competition in pharmaceuticals and related sectors.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  Competition, European Commission, Patents, Pharmaceutical

Published In: Antitrust & Trade Regulation Updates, Civil Procedure Updates, Intellectual Property Updates, International Trade Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© White & Case LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »